Inhibitor Therapeutics Advances Itraconazole Program for Gorlin Syndrome with Novel Amorphous Formulation
Key Insights
Inhibitor Therapeutics (search) is conducting a three-way crossover pharmacokinetic study in Malaysia for its proprietary itraconazole formulation targeting surgically eligible basal cell carcinomas (search) in Gorlin Syndrome (search) patients.
The company's novel amorphous formulation approach addresses significant solubility limitations of conventional crystalline itraconazole, potentially improving intestinal absorption and pharmacokinetic consistency.
This pharmacokinetic study is expected to be the final clinical study required before submitting a New Drug Application to the FDA under the 505(b)(2) regulatory pathway.
Inhibitor Therapeutics (search) is progressing its lead itraconazole program for Gorlin Syndrome (search) through a critical pharmacokinetic study that could pave the way for regulatory submission. The clinical-stage pharmaceutical company announced that its comparative pharmacokinetic, safety and tolerability study is advancing through crossover dosing periods, with results expected to support a New Drug Application (NDA) filing with the FDA.
Novel Formulation Strategy Addresses Drug Solubility Challenges
The company's program centers on a proprietary amorphous formulation of itraconazole designed to overcome significant limitations of the conventional crystalline form. In its traditional crystalline state, itraconazole presents substantial solubility challenges that can contribute to variability in absorption and systemic exposure.
Inhibitor's formulation strategy incorporates itraconazole in an amorphous morphology, which is intended to enhance solubility and dissolution behavior by reducing particle agglomeration and improving dispersion. This approach may support improved intestinal absorption and more consistent, predictable pharmacokinetic performance compared to existing formulations.
The company's Investigational Medicinal Product Dossier characterizes these underlying challenges and supports the scientific rationale for the formulation strategy. While the bulk drug substance is described as crystalline and practically insoluble in water, the formulated product candidate was shown by X-ray diffraction to be amorphous, without detectable crystalline peaks, and was developed with the intent of suppressing crystallization and improving intestinal solubility and absorption.
Clinical Study Timeline and Regulatory Strategy
The three-way crossover study is being conducted in healthy adult subjects under fasting conditions in Malaysia, comparing the proprietary formulation against a reference listed drug. The study is being executed in collaboration with Avior Bio (search), Inc., with the partnership spanning formulation development through clinical execution and proceeding in line with planned timelines and budget.
The study is currently progressing through its crossover dosing periods, with Period 2 scheduled for April 10, 2026, and Period 3 scheduled for April 24, 2026. Following the final pharmacokinetic sampling in Period 3, plasma samples are expected to be shipped for bioanalysis on or about May 1, 2026. Bioanalytical work is expected to require approximately two weeks, followed by approximately two additional weeks of statistical analysis.
The company expects to receive top-line comparative pharmacokinetic and relative bioavailability results in advance of the full Clinical Study Report. Based on Inhibitor's current development plan, this pharmacokinetic study is expected to represent the final clinical study required prior to NDA submission to the FDA for its Basal Cell Carcinoma Nevus Syndrome (search) program under the 505(b)(2) regulatory pathway.
Intellectual Property Enhancement
In parallel with clinical advancement, Inhibitor is preparing a new patent application directed to the composition of its proprietary formulation. The company expects to seek global patent protection for the formulation and, if granted, the patent would be owned by Inhibitor Therapeutics (search) without any ongoing royalty obligations.
The company believes this planned filing has the potential to materially strengthen its intellectual property estate by expanding protection around the formulation itself, complementing its existing portfolio related to the use of itraconazole in oncology indications. If granted, such patent protection could enhance the strategic value of the BCCNS program as it advances toward potential NDA submission, commercialization and broader partnering discussions.
Addressing Unmet Medical Need in Rare Disease
Gorlin Syndrome (search) is a rare hereditary disorder characterized by the development of multiple basal cell carcinomas (search) over a patient's lifetime. Inhibitor is developing itraconazole for surgically eligible BCCs in BCCNS as a differentiated therapeutic approach intended to address a significant unmet need for patients who often face repeated surgical procedures and associated morbidity.
The company positions itself as a clinical-stage pharmaceutical development company focused on developing and commercializing innovative therapies using repurposed, already approved active pharmaceutical ingredients that have clinical value and are patent protected.